Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 20, Issue 22, 2002, Pages 4440-4447

  Herbst, Roy S ^a   Madden, Timothy L ^a   Tran, Hai T ^a   Blumenschein Jr , George R ^a   Meyers, Christina A ^a   Seabroake, Lee F ^a   Khuri, Fadlo R ^a   Puduvalli, Vinay K ^a   Allgood, Victoria ^a   Fritsche Jr , Herbert A ^a   Hinton, Leslie ^a   Newman, Robert A ^a   Crane, Elizabeth A ^a   Fossella, Frank V ^a   Dordal, Margaret ^a   Goodin, Thomas ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADULT; AGED; AGITATION; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CEREBELLUM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; DYSESTHESIA; FATIGUE; FEMALE; GAIT DISORDER; HUMAN; INFECTION; INSOMNIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALE; MENTAL INSTABILITY; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; SPEECH DISORDER; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOHEXANES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SESQUITERPENES; TREATMENT OUTCOME;

EID: 0037112010     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.04.006     Document Type: Article

References (48)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Khuri FR, Herbst RS, Fossella FV: Emerging therapies in non-small-cell lung cancer. Ann Oncol 12:739-744, 2001
3. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-564, 1996
4. Fidler IJ: Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50:6130-6138, 1990
5. Folkman J: Tumor angiogenesis, in Weichselbaum RR (ed): Cancer Medicine (Ed 5). Ontario, Canada, B.C. Decker, 2000, pp 132-152
6. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
7. Fontanini G, Lucchi M, Vignati S, et al: Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: A prospective study. J Natl Cancer Inst 89:881-886, 1997
8. Fontanini G. Bigini D, Vignati S, et al: Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 177:57-63, 1995
9. Gasparini G, Harris AL: Prognostic significance of tumor vascularity, in Teicher BA (ed): Antiangiogenic Agents in Cancer Therapy. Totowa, NJ, Humana Press, 1999, pp 317-339
10. Ingber D, Fujita T, Kishimoto S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557, 1990
11. Sin N, Meng L, Wang MQ, et al: The antiangiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 94:6099-6103, 1997
12. Teicher BA, Holden SA, Ara G, et al: Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 38:169-177, 1996
13. Teicher BA, Emi Y, Kakeji Y, et al: TNP-470/minocycline/cytotoxic therapy: A systems approach to cancer therapy. Eur J Cancer 32A:2461-2466, 1996
14. Response of PC-3 Tumor Combination with TNP-470 and Taxol. Southern Research Institute Report 9102.4.1.3, 1997
15. Herbst RS, Takeuchi H, Teicher BA: Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small cell lung and breast carcinoma models. Cancer Chemother Pharmacol 41:497-504, 1998
16. Teicher BA, Holden SA, Ara G, et al: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 57:920-925, 1994
17. Teicher BA, Holden SA, Dupuis NP, et al: Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 36:227-236, 1995
18. Teicher BA, Dupuis NP, Robinson MF, et al: Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 7:237-243, 1995
19. Murray GI, Paterson PJ, Weaver RJ, et al: The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma. Cancer 71:36-43, 1993
20. Teicher BA, Dupuis NP, Kusumoto T, et al: Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Investig 2:269-276, 1995
21. Johnson DH, Chang AY, Ettinger DS: Taxol (paclitaxel) in the treatment of lung cancer: The Eastern Cooperative Oncology Group experience. Ann Oncol 5:S45-S50, 1994
22. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
23. Socinski MA, Langer CJ: Single-agent paclitaxel and paclitaxel/nonplatinum combination therapy in advanced non-small cell lung cancer. Semin Oncol 26:51-61; discussion 71-72, 1999
24. Kudelka AP, Verschraegen CF, Loyer E: Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 338:991-992, 1998
25. Kudelka AP, Levy T, Verschraegen CF, et al: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3:1501-1505, 1997
26. Logothetis CJ. Wu KK, Finn LD, et al: Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7:1198-1203, 2001
27. Bhargava P, Marshall JL, Rizvi N, et al: A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5:1989-1995, 1999
28. Kano Y, Tamazaki R, Shirair Y, et al: Effects of an injection of anti-bFGF antibody (3H3) and angiogenesis inhibitor (TNP-470) on mouse syngeneic solid tumor (NR-SI). Biotherapy 10:530-532, 1996
29. Fujimoto J, Hori M, Ichigo S, et al: Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Lett 113:187-194, 1997
30. Wechsler D: Wechsler Adult Intelligence Scale-Revised. San Antonio, TX, The Psychological Corporation, 1981
31. Benedict RB, Schretlen D, Groninger L, et al: Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43-55, 1998
32. Benton AL, Hamsher KS: Multilingual Aphasia Examination. Iowa City, IA, AJA Associates, 1989
33. Lezak MD: Neuropsychological Assessment. New York, NY, Oxford University Press, 1983
34. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
35. Whalen CT, Hanson GD, Putzer KJ, et al: Assay of TNP-470 and its two major metabolites in human plasma by high-performance liquid chromatography/mass spectrometry. J Chromatogr Sci 40:214-218, 2002
36. R&D Systems: Quantikine Human VEGF. Minneapolis, MN, R&D Systems, Inc, Catalog Number DVE00
37. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
38. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 14:2054-2060, 1996
39. Taxol (Paclitaxel) [Package Insert]. Bristol Myers Squibb - US, rev 12/12/92; rev 9/96, rev 8/97, rec 7/13/97; rev 7/98, rec 9/24/98, Table 9, p 2
40. DeVore RF, Fehrenbacher RS, Herbst R, et al: A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal to antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel chemotherapy (CP) to CP alone in patients with stage IIIb/IV NSCLC. Proc Am Soc Clin Oncol 19:485a, 2000 (abstr 1896)
41. Kuenen BC, Rosen L, Smit EF, et al: Dose-finding and pharmacokinetic study of cisplatin, genicitabine, and SU 5416 in patients with solid tumors. J Clin Oncol 20:1657-1667, 2002
42. Meyers CA: Neurocognitive dysfunction in cancer patients. Oncology (Huntingt) 14:75-79; discussion 79, 81-72, 85, 2000
43. Schagen SB, van Dam FS, Muller MJ, et al: Cognitive deficits after post-operative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650, 1999
44. Turk BE, Griffith EC, Wolf S, et al: Selective inhibition of aminoterminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 6:823-833, 1999
45. Bergers G, Javaherian K, Lo KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999
46. Figg WD, Pluda JM, Lush RM, et al: The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17:91-97, 1997
47. Blumenschein GR Jr, Fossella FV, Pisters KM, et al: A phase I study of continuous infusion of TNP-470 alone or in combination with paclitaxel and carboplatin in adult patients with solid tumors. Proc Am Soc Clin Oncol 21:314a, 2002 (abstr 1254)
48. Johnson DH, DeVore R, Kabbinavar F, et al: Carboplatin + paclitaxel + RhuMab-VEGF may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 20:315a, 2001 (abstr 1256)